Lack of effect of botulinum toxin on cortical excitability in patients with cranial dystonia

Clinical Neuropharmacology

Volumn 28, Issue 1, 2005, Pages 1-5

  Allam, Nasser ^a   De Oliva Fonte Boa, Paulo Mauricio ^b   Bezerra Tomaz, Carlos Alberto ^b   Brasil Neto, Joaquim Pereira ^b  

^a HOSPITAL DE BASE DO DISTRITO FEDERAL   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Blepharospasm; Botulinum toxin; Silent period; TMS

Indexed keywords

BOTULINUM TOXIN A; BTX A;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL SILENT PERIOD; CRANIAL DYSTONIA; CRANIOFACIAL MALFORMATION; DRUG EFFECT; DRUG EFFICACY; DYSTONIA; ELECTROMYOGRAM; EVOKED MUSCLE RESPONSE; FACE MUSCLE; HUMAN; MEASUREMENT; MUSCLE CONTRACTION; NERVE EXCITABILITY; ORBICULARIS OCULI MUSCLE; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

ADULT; AGED; BLEPHAROSPASM; BOTULINUM TOXINS; DYSTONIA; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; HUMANS; MIDDLE AGED; OCULOMOTOR MUSCLES; SKULL; STATISTICS, NONPARAMETRIC;

EID: 13944284242     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000152044.43822.42     Document Type: Article

References (42)

1. Tolosa E, Montserrat L, Bayse A. Blink reflex studies in focal dystonias: enhanced excitability of brainstem interneurons in cranial dystonia and spasmodic torticollis. Mov Disord. 1988;3:61-69.
2. Cruccu G, Pauletti G, Agostino R, et al. Masseter inhibitory reflex in movement disorders, Huntgton's chorea, Parkinson's disease, dystonia, and unilateral masticatory spasm. Electroencephalogr Clin Neurophysiol. 1991;81:24-30.
3. Eekhof JL, Aramideh M, Bour LJ, et al. Blink reflex recovery curves in blepharospasm, torticollis, and hemifacial spasm. Muscle Nerve. 1996; 19:10-15.
4. Berardelli A, Rothwell JC, Hallet M, et al. The pathophysiology of primary dystonia. Brain. 1998;121:1195-1212.
5. Brasil-Neto JP, McShane LM, Fuhr P, et al. Topographic mapping of the human motor cortex with magnetic stimulation: factors affecting accuracy and reproducibility. Electroencephalogr Clin Neurophysiol. 1992;85:9-16.
6. Sommer M, Ruge D, Tergau F, et al. Intracortical excitability in the hand motor representation in hand dystonia and blepharospasm. Mov Disord. 2002;17:1017-1025.
7. Baker RS, Andersen AH, Morecraft RJ, et al. A functional magnetic resonance imaging study in patients with benign essential blepharospasm. J Neurophthalmol. 2003;23:11-15.
8. Cakmur R, Donmez B, Uzunel F, et al. Evidence of widespread impairment of motor cortical inhibition in focal dystonia: a transcranial magnetic stimulation study in patients with blepharospasm and cervical dystonia. Adv Neurol. 2004;94:37-44.
9. Ellrich J, Treede RD. Characterization of blink reflex interneurons by activation of diffuse noxious inhibitory controls in man. Brain Res. 1998;803:161-168.
10. Gelb DJ, Lowenstein DH, Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of cervical dystonia. Neurology. 1989;39:80-84.
11. Wellhoner HH. Clostridial toxins and the central nervous system: studies on "in situ" tissues. In: Simpson LL, ed. Botulinum Neurotoxin and Tetanus Toxin. San Diego: Academic Press, 1989, pp 231-253.
12. Filippi GM, Errico P, Santarelli R, et al. Botulinum-A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113:400-404.
13. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve. 1996;10:488-496.
14. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155-188.
15. Bigalke H, Heller I, Bizzini B, et al. Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with participate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch Pharmacol. 1981;316:244-251.
16. Priori A, Berardelli A, Mercuri B, et al. Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain. 1995;118:801-807.
17. Valls-Sole J, Tolosa ES, Marti MJ, Allam N. Treatment with botulinum toxin injections does not change brainstem interneuronal excitability in patients with cervical dystonia. Clin Neuropharmacol. 1994;17:229-235.
18. Valls-Sole J, Tolosa ES, Ribera G. Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm. J Neurol Neurosurg Psychiatry. 1991;54:310-313.
19. Byrnes ML, Thickbroom GW, Wilson SA, et al. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain. 1998;121:977-988.
20. Gilio F, Curra A, Lorenzano C, et al. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol. 2000;48:20-26.
21. Ceballos-Baumann AO, Sheean G, et al. Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. Brain. 1997;120:571-582.
22. Esmaeli-Gutstein B, Nahmias C, Thompson M, et al. Positron emission tomography in patients with benign essential blepharospasm. Ophthal Plast Reconstr Surg. 1999;15:23-27.
23. Boroojerdi B, Cohen LG, Hallett M. Effects of botulinum toxin on motor system excitability in patients with writer's cramp. Neurology. 2003;61: 1546-1550.
24. Leis AA, Kofler M, Stokic DS, et al. Effect of the inhibitory phenomenon following magnetic stimulation of the cortex on brainstem motor neuron excitability and on the cortical control of brainstem reflexes. Muscle Nerve. 1993;16:1351-1358.
25. Cruccu G, Inghilleri M, Berardelli A, et al. Cortical mechanisms mediating the inhibitory period after magnetic stimulation of the facial motor area. Muscle Nerve. 1997;20:418-424.
26. Curra A, Romaniello A, Berardelli A, et al. Shortened cortical silent period in facial muscles of patients with cranial dystonia. Neurology. 2000;54:130.
27. Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve. 1991;14:672-675; Comments 677.
28. Habermann E. I-Labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch Pharmacol. 1974;281:47-56.
29. Wiegand H, Erdmann G, Wellhoner HH. I-Labeled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol. 1976;292:161-165.
30. Garner CG, Straube A, Witt TN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord. 1993;8:33-37.
31. Simpson LL. Peripheral actions of the botulinum toxin. In: Botulinum Neurotoxin and Tetanus Toxin. San Diego: Academic Press, 1989, pp 153-178.
32. Crosby EC, Humphrey T, Lauer EW. Correlative Anatomy of the Nervous System. New York: Macmillan, 1962, pp 161-165.
33. Folkins JW, Larson CR. In search of a tonic vibration reflex in the human lip. Brain Res. 1978;151:409-412.
34. Lorente de No R. Vestibulo-ocular reflex arc. Arch Neurol Psychiatry, 1933;30:245-291.
35. Poppele RE. The muscle spindle. In Dyck PJ, Thomas PK, eds. Peripheral Neuropathy, 3rd ed, vol 1. Philadelphia: WB Saunders, 1993, 21-140.
36. Ridding MC, Sheean G, Rothwell JC, et al. Changes in the balance between motor cortical excitation and inhibition in focal, task specific dystonia. J Neurol Neurosurg Psychiatry. 1995;59:493-498.
37. Schicatano EJ, Basso MA, Evinger C. Animal model explains the origins of the cranial dystonia benign essential blepharospasm. J Neurophysiol. 1997;77:2842-2846.
38. Basso MA, Powers AS, Evinger C. An explanation for reflex blink hyperexcitability in Parkinson's disease. I. Superior colliculus. J Neurosci. 1996;16:7308-7317.
39. Hallett M. Blepharospasm: recent advances. Neurology. 2002;59:1306-1312.
40. Baker RS, Sun WS, Hasan SA, et al. Maladaptive neural compensatory mechanisms in Bell's palsy-induced blepharospasm. Neurology. 1997; 49:223-229.
41. Chuke JC, Baker RS, Porter JD. Bell's palsy-associated blepharospasm relieved by aiding eyelid closure. Ann Neurol. 1996;39:263-268.
42. 125I-botulinum- free neurotoxin: time course of tissue distribution. Toxicon. 2003;42:461-469.